AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01393158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
Study NCT00924521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain diet
Description: Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
Study NCT00924521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain
Description: Participants in this group will receive only refined grains as typically consumed in the average American diet.
Study NCT02324881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Use PSMA
Study NCT02324881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02547311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Clinic
Study NCT04233801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT04233801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02113696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 intake, morbid obesity
Description: Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
Study NCT02113696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Capsules
Description: They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Study NCT03272802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
Study NCT03272802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
Study NCT03272802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
Study NCT02755428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retinal pigment epithelium transplantation
Description: Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
Study NCT02421172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: CJM112 Fully human IgG1 monoclonal antibody
Study NCT02421172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01366768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral amino acid mixture
Description: Amino acid mixture 2,93 ml/kg
Study NCT01366768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid administration
Description: Amino acid mixture 2,93 ml/kg
Study NCT01841281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Study NCT01841281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
Study NCT04058938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational handout instrument
Description: The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
Study NCT04058938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard patient counseling
Study NCT03112681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 2 mg
Description: Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
Study NCT03112681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4 mg
Description: Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
Study NCT03112681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Study NCT00558142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
Study NCT00558142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: 100mls IV dose as single dose
Study NCT00558142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
Study NCT02206204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag
Study NCT02206204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for selexipag
Study NCT00599872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Ragweed Allergenic Extract
Description: Standardized Ragweed Allergenic Extract, sublingual oral
Study NCT00599872 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sublingual oral
Study NCT04013386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant and Dexamethasone
Description: Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
Study NCT04013386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine and Dexamethasone
Description: Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
Study NCT04013386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IVI
Study NCT01343953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Transplantation
Description: One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
Study NCT03629886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV (Types 16, 18) Vaccine, Adsorbed
Description: Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
Study NCT03011008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
Study NCT03011008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Receive insulin following clinician's instruction.
Study NCT03011008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Receive insulin following clinician's instruction.
Study NCT00764699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF (Increlex)
Description: rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
Study NCT05296226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling and ischemic compression
Description: dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
Study NCT01572597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10RAC+acetylcystein
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
Study NCT01572597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10RAC+metronidazole
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
Study NCT04006041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
Study NCT04006041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Description: Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
Study NCT04006041 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
Study NCT04006041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
Study NCT01090479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine cloth
Description: The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
Study NCT00469573 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1. Optive
Description: Optive 15ml- (in the eye) Instill one drop twice daily in each eye
Study NCT02107417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TENS
Description: Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
Study NCT02107417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo TENS
Description: who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
Study NCT04404426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Administration of citrulline enterally for 7 days.
Study NCT04404426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (water) enterally for 7 days
Study NCT00190437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic
Description: Amoxicillin-clavulanic
Study NCT00672555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limberg-flap
Description: Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
Study NCT01941511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
Study NCT01991392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: For nasogastric decompression.
Study NCT01991392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nasogastric tube
Description: For nasogastric decompression.
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies
Study NCT01019187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study NCT04393753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domatinostat in combination with avelumab
Description: domatinostat tablets and avelumab infusion
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pictilisib
Description: Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
Study NCT01019187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fatigue Assessment and Management
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep Disorder Therapy
Study NCT01019187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Given orally
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01019187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatigue Assessment and Management
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep disorder therapy
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of Life assessment
Description: Ancillary Studies
Study NCT01019187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01019187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given orally
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatigue assessment and management
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of therapy and complications
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Quality of Life Assessment
Study NCT01019187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatifue assessment and management
Study NCT00703456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: balance training three days per week for 4 weeks during single limb standing
Study NCT03182374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nSTRIDE APS
Description: Intra-articular injection
Study NCT03182374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Intra-articular injection
Study NCT04218201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCP brief advice
Description: Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
Study NCT04218201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video doctor
Description: During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
Study NCT04218201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone health coaching
Description: All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
Study NCT04218201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Care Manager (NCM) intervention
Description: NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
Study NCT04487041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
Study NCT04487041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
Study NCT04487041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle